Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP

Steck, Susan E.; Arab, Lenore; Zhang, Hongmei; Bensen, Jeannette T.; Fontham, Elizabeth T.H.; Johnson, Candace S.; Mohler, James L.; Smith, Gary J.; Su, Joseph; Trump, Donald L.; Woloszynska‐Read, Anna

doi:10.1371/journal.pone.0125151

Cited by 22 publications

(20 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 Kristal and colleagues 1 demonstrated a U-shaped relationship between vitamin D and prostate cancer risk based on prospective, multi-institutional data collected in the Selenium and Vitamin E Cancer Prevention Trial. Similarly, Schenck and colleagues 2 showed an increased risk of aggressive PCa among men with low vitamin D. Additionally, Steck and colleagues 24 showed that low 25-OH D levels were associated with aggressive PCa among AA men in the North Carolina-Louisiana Prostate Cancer Project, and this relationship was modified negatively by low calcium intake. However, there are a couple of methodological differences—such as timing of blood draw, which was several months after PCa diagnosis in their cohort and different risk strata definitions—that may explain disparities in some of the results from our respective cohorts.…”

Section: Discussionmentioning

confidence: 94%

Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy

Nyame

Bowen

Jordan

et al. 2016

JCO

View full text Add to dashboard Cite

Purpose Lower serum Vitamin D levels has demonstrated associations with increased risk of aggressive prostate cancer. Among men with localized prostate cancer, especially with low- or intermediate risk disease, vitamin D may serve as an important biomarker of disease aggression. The aim of this study is to assess the relationship between adverse pathology at the time of radical prostatectomy and serum 25-hydroxyvitamin (25-OH D) levels. Patients and Methods This is a cross-sectional study from 2009 to 2014, nested within a large epidemiologic study of 1,760 healthy controls and men undergoing prostate cancer. In total, 190 men underwent radical prostatectomy in the cohort. Adverse pathology was defined as the presence of primary Gleason 4 or any Gleason 5 disease, or extra-prostatic extension. Descriptive and multivariate analyses were performed to assess the relationship between 25-OH D and adverse pathology at the time of prostatectomy. Results 45.8 % (87/190) of men in this cohort demonstrated adverse pathology at radical prostatectomy. The median age in the cohort was 64.0 years (IQR 59.0–67.0). On univariate analysis men with adverse pathology at radical prostatectomy demonstrated lower median serum 25-OH D (22.7 vs 27.0 ng/ml, p = 0.007) when compared to their counterparts. On multivariate analysis controlling for age, serum PSA, and suspicious digital rectal examination, serum 25-OH D < 30 ng/mL was associated with increased odds of adverse pathology (OR 2.64, 95% CI 1.25, 5.59, p = 0.01). Conclusion Insufficiency/Deficiency in serum 25-OH D is associated with increased odds of adverse pathology in men with localized disease undergoing radical prostatectomy. Serum 25-OH D may serve as a useful biomarker in prostate cancer aggressiveness, which deserves continued study.

show abstract

Section: Discussionmentioning

confidence: 94%

Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy

Nyame

Bowen

Jordan

et al. 2016

JCO

View full text Add to dashboard Cite

show abstract

“…Previous investigations of black men have been largely retrospective 12,14,17 or cross-sectional analyses, 13 both of which are limited with respect to establishing a temporal relationship between vitamin D and prostate cancer risk. Only two race-specific studies examined the association between prediagnostic circulating 25(OH)D and prostate cancer risk in black men.…”

Section: Discussionmentioning

confidence: 99%

“…7 There remains, however, a paucity of research examining the relationship between black race, vitamin D status, and prostate cancer risk. [11][12][13][14][15][16][17] In this prospective nested case-control study, we examine the association between prostate cancer risk and serum vitamin D status among black men in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.…”

Section: Introductionmentioning

confidence: 99%

Serum 25‐hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men

Layne

Weinstein

Graubard

et al. 2017

Cancer

View full text Add to dashboard Cite

BACKGROUND Few studies have prospectively examined the relationship between vitamin D status and prostate cancer risk in black men, a group at high risk for both low vitamin D status and prostate cancer. METHODS Among black men in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, we identified 226 prostate cancer cases and 452 controls matched on age at randomization (±5 years), date of blood draw (±30 days), calendar year of cohort entry, and time since baseline prostate cancer screening (±1 year). Conditional logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between serum 25-hydroxyvitamin D [25(OH)D], vitamin D binding protein (DBP), the 25(OH)D:DBP molar ratio, and prostate cancer risk. RESULTS Serum 25(OH)D was not associated with overall prostate cancer (Q4 vs Q1: OR, 0.73; 95% CI, 0.40–1.33; P for trend = .25), although there were apparent inverse associations for nonaggressive disease (global P = .03, clinical stage I/II, and Gleason score <7) and among men ≥62 years old (P for interaction = .04) that were restricted to Q3. Interestingly, serum DBP was significantly inversely associated with prostate cancer risk (Q4 vs Q1: OR, 0.45; 95% CI, 0.20–1.00; P for trend = .03), whereas the 25(OH)D:DBP molar ratio was not. Results were similar when we mutually adjusted for 25(OH)D and DBP, and we found no evidence of interaction between the two. CONCLUSION Our study suggests higher (versus lower) circulating DBP may be independently associated with a decreased prostate cancer risk in black men independent of 25(OH)D status.

show abstract

“…Studies to date on circulating vitamin D and prostate cancer risk in black men include retrospective, hospitalbased, case-control (120)(121)(122), and cross-sectional analyses (123,124). Among the prospective evaluations in black men, the number of cases has been relatively small (n = 91-250), contributing to imprecise risk estimates and inconsistent findings across studies (22,125,126) (Table 3).…”

Section: Blood Concentrations Of 25(oh)dmentioning

confidence: 99%

Vitamin D and Cancer Risk and Mortality: State of the Science, Gaps, and Challenges

Mondul

Weinstein

Layne

et al. 2017

Epidemiologic Reviews

162

133

View full text Add to dashboard Cite

There has been substantial enthusiasm recently regarding the potential role of vitamin D in the primary and secondary prevention of cancer. Laboratory studies demonstrate a range of anticarcinogenic effects for vitamin D compounds, but human studies have yielded little consistent evidence supporting a protective association. Higher circulating levels of vitamin D (i.e., 25-hydroxyvitamin D or 25(OH)D) appear to be associated with reduced risk of colorectal and bladder malignancies, but higher risk of prostate and possibly pancreatic cancers, with no clear association for most other organ sites examined. Despite there being no official institutional recommendations regarding the use of vitamin D supplements for cancer prevention, screenings for vitamin D deficiency and vitamin D supplement use have increased substantially over the past decade. These widespread practices demonstrate that population sociobehavioral changes are often adopted before scientifically well-informed policies and recommendations are available. This review critically examines the currently available epidemiologic literature regarding the associations between circulating 25(OH)D, vitamin D supplementation, and vitamin D-related genetic variation and cancer risk and mortality, with a particular emphasis on prospective studies. We identify several important gaps in our scientific knowledge that should be addressed in order to provide sufficient reproducible data to inform evidence-based recommendations related to optimal 25(OH)D concentrations (and any role for vitamin D supplementation) for the primary and secondary prevention of cancer. With few exceptions, such recommendations cannot be made at this time.

show abstract

Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP

Cited by 22 publications

References 60 publications

Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy

Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy

Serum 25‐hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men

Vitamin D and Cancer Risk and Mortality: State of the Science, Gaps, and Challenges

Contact Info

Product

Resources

About